The effect of anti-resorptive therapies on bone graft healing in an ovariectomized rat spinal arthrodesis model

Bone

Volumn 43, Issue 6, 2008, Pages 1057-1066

  Takahata, Masahiko ^a   Ito, Manabu ^a   Abe, Yuichiro ^a   Abumi, Kuniyoshi ^a   Minami, Akio ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti resorptive drug; Bisphosphonate; Bone graft; Selective estrogen receptor modulator (SERM); Spine fusion

Indexed keywords

ALENDRONIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; MESSENGER RNA; OSTEOCALCIN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRODESIS; ARTICLE; BONE GRAFT; BONE REMODELING; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; NONHUMAN; NUCLEOTIDE SEQUENCE; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OVARIECTOMY; POSTOPERATIVE PERIOD; RAT; SPINAL ARTHRODESIS; SPINE FUSION; SPINE SURGERY; THREE DIMENSIONAL IMAGING;

ANIMALS; BASE SEQUENCE; BONE TRANSPLANTATION; DIPHOSPHONATES; DNA PRIMERS; FEMALE; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SPINAL DISEASES; TOMOGRAPHY, X-RAY COMPUTED; WOUND HEALING;

EID: 57049169140     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2008.08.124     Document Type: Article

References (36)

1. Abe Y., Takahata M., Ito M., Irie K., Abumi K., and Minami A. Enhancement of graft bone healing by intermittent administration of human parathyroid hormone (1-34) in a rat spinal arthrodesis model. Bone 41 (2007) 775-785
2. Babat L.B., McLain R., Milks R., Ferrara L., and Sohn M.J. The effects of the antiresorptive agents calcitonin and pamidronate on spine fusion in a rabbit model. Spine J. 5 (2005) 542-547
3. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 (1996) 1535-1541
4. Boden S.D., Titus L., Hair G., Liu Y., Viggeswarapu M., Nanes M.S., et al. Lumbar spine fusion by local gene therapy with a cDNA encoding a novel osteoinductive protein (LMP-1). Spine 23 (1998) 2486-2492
5. Boden S.D. Overview of the biology of lumbar spine fusion and principles for selecting a bone graft substitute. Spine 27 (2002) S26-S31
6. Bransford R., Goergens E., Briody J., Amanat N., Cree A., and Little D. Effect of zoledronic acid in an L6-L7 rabbit spine fusion model. Eur. Spine J. 16 (2007) 557-562
7. Bridwell K.H., Sedgewick T.A., O'Brien M.F., Lenke L.G., and Baldus C. The role of fusion and instrumentation in the treatment of degenerative spondylolisthesis with spinal stenosis. J. Spinal Disord. 6 (1993) 461-472
8. Cao Y., Mori S., Mashiba T., Westmore M.S., Ma L., Sato M., et al. Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J. Bone Miner. Res. 17 (2002) 2237-2246
9. Corey E., Brown L.G., Quinn J.E., Poot M., Roudier M.P., Higano C.S., et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin. Cancer Res. 9 (2003) 295-306
10. Coxon F.P., Helfrich M.H., Van't Hof R., Sebti S., Ralston S.H., Hamilton A., et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J. Bone Miner. Res. 15 (2000) 1467-1476
11. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. Jama 280 (1998) 2077-2082
12. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Jama 282 (1999) 637-645
13. Hidaka C., Goshi K., Rawlins B., Boachie-Adjei O., and Crystal R.G. Enhancement of spine fusion using combined gene therapy and tissue engineering BMP-7-expressing bone marrow cells and allograft bone. Spine 28 (2003) 2049-2057
14. Huang R.C., Khan S.N., Sandhu H.S., Metzl J.A., Cammisa Jr. F.P., Zheng F., et al. Alendronate inhibits spine fusion in a rat model. Spine 30 (2005) 2516-2522
15. Jilka R.L., Hangoc G., Girasole G., Passeri G., Williams D.C., Abrams J.S., et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 257 (1992) 88-91
16. Lehman Jr. R.A., Kuklo T.R., Freedman B.A., Cowart J.R., Mense M.G., and Riew K.D. The effect of alendronate sodium on spinal fusion: a rabbit model. Spine J. 4 (2004) 36-43
17. Li J., Mori S., Kaji Y., Kawanishi J., Akiyama T., and Norimatsu H. Concentration of bisphosphonate (incadronate) in callus area and its effects on fracture healing in rats. J. Bone Miner. Res. 15 (2000) 2042-2051
18. Little D.G., Smith N.C., Williams P.R., Briody J.N., Bilston L.E., Smith E.J., et al. Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis. J. Bone Miner. Res. 18 (2003) 1300-1307
19. McGuire R.A., and Amundson G.M. The use of primary internal fixation in spondylolisthesis. Spine 18 (1993) 1662-1672
20. Mofidi A., Sedhom M., O'Shea K., Fogarty E.E., and Dowling F. Is high level of disability an indication for spinal fusion? Analysis of long-term outcome after posterior lumbar interbody fusion using carbon fiber cages. J. Spinal Disord. Tech. 18 (2005) 479-484
21. Owens J.M., Fuller K., and Chambers T.J. Osteoclast activation: potent inhibition by the bisphosphonate alendronate through a nonresorptive mechanism. J. Cell Physiol. 172 (1997) 79-86
22. Peter C.P., Cook W.O., Nunamaker D.M., Provost M.T., Seedor J.G., and Rodan G.A. Effect of alendronate on fracture healing and bone remodeling in dogs. J. Orthop. Res. 14 (1996) 74-79
23. Rogers M.J., Gordon S., Benford H.L., Coxon F.P., Luckman S.P., Monkkonen J., et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 (2000) 2961-2978
24. Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr. Pharm. Des. 9 (2003) 2643-2658
25. Sama A.A., Khan S.N., Myers E.R., Huang R.C., Cammisa Jr. F.P., Sandhu H.S., et al. High-dose alendronate uncouples osteoclast and osteoblast function: a study in a rat spine pseudarthrosis model. Clin. Orthop. Relat. Res. (2004) 135-142
26. Schimandle J.H., and Boden S.D. Spine update. The use of animal models to study spinal fusion. Spine 19 (1994) 1998-2006
27. Smith E.J., McEvoy A., Little D.G., Baldock P.A., Eisman J.A., and Gardiner E.M. Transient retention of endochondral cartilaginous matrix with bisphosphonate treatment in a long-term rabbit model of distraction osteogenesis. J. Bone Miner. Res. 19 (2004) 1698-1705
28. Smith E.J., Little D.G., Briody J.N., McEvoy A., Smith N.C., Eisman J.A., et al. Transient disturbance in physeal morphology is associated with long-term effects of nitrogen-containing bisphosphonates in growing rabbits. J. Bone Miner. Res. 20 (2005) 1731-1741
29. Suzuki K., Takeyama S., Sakai Y., Yamada S., and Shinoda H. Current topics in pharmacological research on bone metabolism: inhibitory effects of bisphosphonates on the differentiation and activity of osteoclasts. J. Pharmacol. Sci. 100 (2006) 189-194
30. Taranta A., Brama M., Teti A., De luca V., Scandurra R., Spera G., et al. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 30 (2002) 368-376
31. Tou L., Quibria N., and Alexander J.M. Regulation of human cbfa1 gene transcription in osteoblasts by selective estrogen receptor modulators (SERMs). Mol. Cell. Endocrinol. 183 (2001) 71-79
32. Van Offel J.F., Schuerwegh A.J., Bridts C.H., Stevens W.J., and De Clerck L.S. Effect of bisphosphonates on viability, proliferation, and dexamethasone-induced apoptosis of articular chondrocytes. Ann. Rheum. Dis. 61 (2002) 925-928
33. Viereck V., Grundker C., Blaschke S., Niederkleine B., Siggelkow H., Frosch K.H., et al. Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J. Clin. Endocrinol. Metab. 88 (2003) 4206-4213
34. West III J.L., Bradford D.S., and Ogilvie J.W. Results of spinal arthrodesis with pedicle screw-plate fixation. J. Bone Joint Surg. Am. 73 (1991) 1179-1184
35. Xue Q., Li H., Zou X., Bunger M., Egund N., Lind M., et al. The influence of alendronate treatment and bone graft volume on posterior lateral spine fusion in a porcine model. Spine 30 (2005) 1116-1121
36. Zdeblick T.A. A prospective, randomized study of lumbar fusion. Preliminary results. Spine 18 (1993) 983-991